Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Avrina
- Development stage
- Discontinued
- Lead developer
- Anesiva
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Topical
01
Overview
Avrina (NF-kappaB Decoy) is a synthetic double-stranded decoy oligonucleotide therapeutic designed to treat inflammatory diseases, specifically atopic dermatitis. It functions by mimicking the specific DNA binding sequence of the transcription factor NF-kappaB. By acting as a molecular sink, the decoy sequestered NF-kappaB proteins, preventing them from binding to endogenous promoter regions in the nucleus and thereby inhibiting the transcription of pro-inflammatory cytokines and adhesion molecules. Originally developed by Corgentech (which later merged with AlgoRx to form Anesiva), the drug was evaluated in Phase 1/2 clinical trials for mild-to-moderate atopic dermatitis. In 2008, Anesiva out-licensed the worldwide rights for the program to Transcription Factor Therapeutics (TFT).
- Brand names
- Avrina
- Other names
- NF-kappaB DecoyNF-kappaB decoy oligonucleotideNF-kB decoy
02
Targets
NF-κB
Beyond the preview
Go deeper on Avrina.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Avrina.